Narrator: This is Science Today. A new designer estrogen called reloxifen not only reduces the number of fractures in women with osteoporosis, but also lowers the risk of invasive breast cancer. Dr. Steven Cummings of the University of California, San Francisco, led a large study on the drug.
Cummings: The main reason for studying reloxifen was to see if it reduced the risk of fractures. But we've also discovered that during the past thirty-three months of follow-up, that women who were taking reloxifen had a seventy percent lower risk of invasive breast cancer than women who were taking the placebo.
Narrator: And the risk of an estrogen-stimulated form of breast cancer common in women over 65 was reduced by eighty-seven percent.
Cummings: This might be a good option for women who are interested in doing something for prevention of fractures and are scared of the possibility that estrogen might increase risk of breast cancer.
Narrator: Unlike tamoxifen, another designer estrogen, there's no risk of endometrial cancer with reloxifen. For Science Today, I'm Larissa Branin.